Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2013 | -5.59 Million USD | 90.58% |
| 2012 | -59.42 Million USD | -9.35% |
| 2011 | -54.33 Million USD | 14.43% |
| 2010 | -63.49 Million USD | 45.31% |
| 2009 | -116.1 Million USD | -382.98% |
| 2008 | -24.03 Million USD | 77.76% |
| 2007 | -108.07 Million USD | 26.53% |
| 2006 | -147.1 Million USD | -960.93% |
| 2005 | -13.86 Million USD | -736.81% |
| 2004 | -1.65 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2014 Q1 | -4.85 Million USD | 13.24% |
| 2014 Q2 | -3.39 Million USD | 30.0% |
| 2013 FY | -5.59 Million USD | 90.58% |
| 2013 Q1 | -38.59 Million USD | 35.05% |
| 2013 Q3 | -6.85 Million USD | 34.76% |
| 2013 Q4 | -5.59 Million USD | 18.32% |
| 2013 Q2 | -10.5 Million USD | 72.79% |
| 2012 Q3 | -79.16 Million USD | -0.55% |
| 2012 Q1 | -49.77 Million USD | 8.4% |
| 2012 FY | -59.42 Million USD | -9.35% |
| 2012 Q4 | -59.42 Million USD | 24.94% |
| 2012 Q2 | -78.73 Million USD | -58.17% |
| 2011 Q4 | -54.33 Million USD | 17.7% |
| 2011 Q3 | -66.02 Million USD | 10.28% |
| 2011 Q1 | -96.14 Million USD | -51.41% |
| 2011 FY | -54.33 Million USD | 14.43% |
| 2011 Q2 | -73.59 Million USD | 23.46% |
| 2010 Q1 | -59.14 Million USD | 49.06% |
| 2010 FY | -63.49 Million USD | 45.31% |
| 2010 Q4 | -63.49 Million USD | -26.38% |
| 2010 Q2 | -58.8 Million USD | 0.59% |
| 2010 Q3 | -50.24 Million USD | 14.55% |
| 2009 FY | -116.1 Million USD | -382.98% |
| 2009 Q1 | -79.68 Million USD | -231.48% |
| 2009 Q2 | -75.58 Million USD | 5.15% |
| 2009 Q3 | -67.33 Million USD | 10.91% |
| 2009 Q4 | -116.1 Million USD | -72.42% |
| 2008 Q4 | -24.03 Million USD | 37.12% |
| 2008 Q1 | -86.22 Million USD | 20.22% |
| 2008 FY | -24.03 Million USD | 77.76% |
| 2008 Q2 | -70.19 Million USD | 18.59% |
| 2008 Q3 | -38.23 Million USD | 45.53% |
| 2007 Q2 | -78.03 Million USD | 6.09% |
| 2007 Q4 | -108.07 Million USD | -108.83% |
| 2007 Q3 | -51.75 Million USD | 33.68% |
| 2007 Q1 | -83.09 Million USD | 43.51% |
| 2007 FY | -108.07 Million USD | 26.53% |
| 2006 Q2 | -8.76 Million USD | 40.03% |
| 2006 Q3 | -40.56 Million USD | -362.82% |
| 2006 Q4 | -147.1 Million USD | -262.64% |
| 2006 Q1 | -14.61 Million USD | -5.4% |
| 2006 FY | -147.1 Million USD | -960.93% |
| 2005 FY | -13.86 Million USD | -736.81% |
| 2005 Q4 | -13.86 Million USD | 0.0% |
| 2004 Q4 | -1.65 Million USD | 0.0% |
| 2004 FY | -1.65 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -427151.908% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 199.091% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.079% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2142.208% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1935.082% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 11.222% |
| Qrons Inc. | 351.42 Thousand USD | 1692.649% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 999.313% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 112.886% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -27325.519% |
| Skye Bioscience, Inc. | -5.72 Million USD | 2.174% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 135.507% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 235.915% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1492.812% |
| SQZ Biotechnologies Company | -36.23 Million USD | 84.555% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 349.617% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 703.654% |
| Mesoblast Limited | 55.85 Million USD | 110.02% |
| Marizyme, Inc. | 18.56 Million USD | 130.142% |
| Genus plc | 190.6 Million USD | 102.937% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 350.332% |
| Pharming Group N.V. | 109.8 Million USD | 105.097% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 750.632% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 561.08% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 923.088% |
| ContraFect Corporation | -6.02 Million USD | 7.119% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4257.042% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 584.409% |
| IMV Inc. | 7.67 Million USD | 172.968% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 201.729% |
| MultiCell Technologies, Inc. | 90.04 USD | 6216226.166% |
| ONE Bio Corp. | 9.04 Million USD | 161.913% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -662.557% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 143.233% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 509.146% |
| Q BioMed Inc. | 4.06 Million USD | 237.857% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 118.318% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 655.414% |
| Biomind Labs Inc. | 711.4 Thousand USD | 886.756% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.244% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 379.935% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 143.704% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1655.976% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4103.462% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 28272.346% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 354.18% |
| GB Sciences, Inc. | 1.74 Million USD | 420.32% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -2945.357% |
| HST Global, Inc. | 96.79 Thousand USD | 5882.443% |
| CSL Limited | 10.52 Billion USD | 100.053% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2814.131% |
| Halberd Corporation | 144.72 Thousand USD | 3967.441% |
| Enzolytics Inc. | 981.65 Thousand USD | 670.159% |
| Agentix Corp. | 37.63 Thousand USD | 14973.376% |
| Resverlogix Corp. | 6.45 Million USD | 186.762% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -731.539% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.724% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 88.095% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 179.155% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 306.637% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 36.685% |
| AVAX Technologies, Inc. | -5.9 Million USD | 5.187% |
| Zenith Capital Corp. | 10.06 Thousand USD | 55714.07% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.473% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2892.468% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 334.573% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3502.245% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -30454.646% |
| Kadimastem Ltd | -253.1 Thousand USD | -2111.361% |
| Helix BioMedix, Inc. | -2.57 Million USD | -117.779% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 127.604% |
| BioStem Technologies, Inc. | 4.47 Million USD | 225.156% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2881.063% |
| LadRx Corporation | -2.03 Million USD | -174.838% |
| Cell Source, Inc. | 9.23 Million USD | 160.626% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 981.186% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 981.186% |
| NovAccess Global Inc. | 2.17 Million USD | 356.924% |
| Itoco Inc. | 228.3 Thousand USD | 2551.545% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4215.774% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 212.911% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1255.851% |
| CytoDyn Inc. | 20.26 Million USD | 127.623% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -864969.552% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -60288.376% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 172.632% |
| SYBLEU INC | 473.71 Thousand USD | 1281.515% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 225.577% |
| International Stem Cell Corporation | 2.59 Million USD | 316.1% |
| Bioxytran, Inc. | 1.89 Million USD | 394.747% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9067.683% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 356.637% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 262.988% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 165.439% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 824.43% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -347.76% |
| Neutra Corp. | 52.18 Thousand USD | 10824.893% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -124.869% |
| PureTech Health plc | -167.19 Million USD | 96.652% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2185.348% |
| IXICO plc | -4.44 Million USD | -25.928% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 142.341% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.204% |
| CSL Limited | 10.52 Billion USD | 100.053% |
| Cellectis S.A. | -43.81 Million USD | 87.227% |